Potential of Preventive Treatment of Alzheimer’s Disease: Results of a Three-Year Prospective Open Comparative Trial of the Efficacy and Safety of Courses of Treatment with Cerebrolysin and Cavinton in Elderly Patients with Mild Cognitive Impairment Syndrome

Si, Gavrilova; Колыхалов, И. В.; Fedorova, Ya. B.; Selezneva, N. D.; Kalyn, Ya. B.; Roshchina, I. F.; Odinak, M. M.; Emelin, A. Yu.; Kashin, A V; Густов, А. В.; Антипенко, Е. А.; Korshunova, Yu. A.; Давыдова, Т. А.; Messler, Gail

doi:10.1007/s11055-011-9427-4

Cited by 8 publications

(16 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These compounds can be largely categorized into anti‐amyloid agents and medications that target other pathophysiological pathways (Tables ). Developments in AD prevention and treatment include anti‐amyloid drugs; methods to hyperphosphorylate tau; and neuroprotective and neurotrophic approaches, such as those involving neurotrophins, neurotrophic factors and stem cells . Neurotrophic agents such as cerebrolysin modulate the apoptosis rate of neurons in patients affected by neurodegenerative diseases and are a novel treatment option for AD .…”

Section: Treatment Strategies For Alzheimer's Diseasementioning

confidence: 99%

The ubiquitin proteasomal system: a potential target for the management of Alzheimer's disease

Gadhave

Bolshette

Ahire

et al. 2016

J Cellular Molecular Medi

View full text Add to dashboard Cite

The cellular quality control system degrades abnormal or misfolded proteins and consists of three different mechanisms: the ubiquitin proteasomal system (UPS), autophagy and molecular chaperones. Any disturbance in this system causes proteins to accumulate, resulting in neurodegenerative diseases such as amyotrophic lateral sclerosis, Alzheimer's disease (AD), Parkinson's disease, Huntington's disease and prion or polyglutamine diseases. Alzheimer's disease is currently one of the most common age‐related neurodegenerative diseases. However, its exact cause and pathogenesis are unknown. Currently approved medications for AD provide symptomatic relief; however, they fail to influence disease progression. Moreover, the components of the cellular quality control system represent an important focus for the development of targeted and potent therapies for managing AD. This review aims to evaluate whether existing evidence supports the hypothesis that UPS impairment causes the early pathogenesis of neurodegenerative disorders. The first part presents basic information about the UPS and its molecular components. The next part explains how the UPS is involved in neurodegenerative disorders. Finally, we emphasize how the UPS influences the management of AD. This review may help in the design of future UPS‐related therapies for AD.

show abstract

Section: Treatment Strategies For Alzheimer's Diseasementioning

confidence: 99%

The ubiquitin proteasomal system: a potential target for the management of Alzheimer's disease

Gadhave

Bolshette

Ahire

et al. 2016

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…Показана клиническая эффективность препарата церебролизин (Ц) в комплексной терапии неврологических [18,19] и нейродегенеративных заболеваний, включая БА и MCI [20][21][22]. Ц содержит аминокислоты (85%) и пептиды (15%) нейротрофинов, энкефалинов, орексина, галанина, нейротрансмиттеров.…”

unclassified

Anti-inflammatory effects of neurotrophic therapy (a pilot study)

Malashenkova

Krynskiy

Hailov

et al. 2018

Z. nevrol. psikhiatr. im. S.S. Korsakova

Self Cite

View full text Add to dashboard Cite

show abstract

“…The present study is a continuation of our work with further analysis of data obtained previously [9]. The main aim is to identify the most informative clinical attributes (e.g.…”

Section: Introductionmentioning

confidence: 87%

“…This comparative controlled multi-center clinical study followed MCI subjects with no prominent vascular disorders who were on long-term therapy with cerebrolysin (regular four-week courses, twice a year) with an aim to prevent further cognitive decline and conversion to AD. In general, cerebrolysin demonstrated its high efficacy in prevention of cognitive decline and dementia development within three years in groups of 37 [10] and 55 [9] MCI patients.…”

Section: Introductionmentioning

confidence: 94%

“…One way of addressing this is to use baseline and repeated screening data from long-term longitudinal studies on MCI. One such study is published by Gavrilova et al [9]. This comparative controlled multi-center clinical study followed MCI subjects with no prominent vascular disorders who were on long-term therapy with cerebrolysin (regular four-week courses, twice a year) with an aim to prevent further cognitive decline and conversion to AD.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Progression of Cognitive Deficit in Older People with Mild Cognitive Impairment Treated with Cerebrolysin

Boksha¹,

Гаврилова²,

Колыхалов³

et al. 2014

Health

View full text Add to dashboard Cite

Objectives: Although people with amnestic mild cognitive impairment (aMCI) benefit from cerebrolysin treatment, some still develop dementia. The aim of the current study was to identify most informative clinical assessment tests to predict the therapy efficacy in aMCI subjects treated with cerebrolysin. Methods: We studied patients with amnestic mild cognitive impairment (aMCI; n = 53) who had regular neurocognitive and clinical psychiatric assessments and were treated with cerebrolysin i.v. infusions 20 × 30 ml twice a year over three years period. Data were analyzed using non-parametric statistics, cluster and linear discriminant analyses. Results: Combined mathematical modeling enabled to predict cognitive decline from aMCI to dementia in the cerebrolysin-treated patients based on their initial neurocognitive assessment scores. We identified a "dementia risk group" with fast cognitive decline (i.e. low efficacy of the treatment). Lower baseline scores in the Mattis Dementia Rating Scale Memory subtest, Mini-Mental State Examination (MMSE), 10 word list immediate recall, and Frontal Assessment Battery tests when accompanied by higher depression score (Hamilton Depression Rating Scale) suggest poor prognosis for aMCI patients treated with cerebrolysin. Changes in scores on the MMSE, Boston naming test, Digit span forward, and Wechsler scale subtest "Categorical associations" during the treatment course are more characteristic for patients who convert to dementia than their initial scores. Conclusions: aMCI subjects treated with cerebrolysin with lower baseline cognitive functioning and subclinical depres-I. S. Boksha et al. 2582 sion have poor prognosis in terms of converting to dementia. Changes in the MMSE, Boston naming test, Digit span forward, and Wechsler scale subtest "Categorical associations" scores during the treatment course are more informative to identify patients who will develop dementia than their initial scores.

show abstract

Potential of Preventive Treatment of Alzheimer’s Disease: Results of a Three-Year Prospective Open Comparative Trial of the Efficacy and Safety of Courses of Treatment with Cerebrolysin and Cavinton in Elderly Patients with Mild Cognitive Impairment Syndrome

Cited by 8 publications

References 13 publications

The ubiquitin proteasomal system: a potential target for the management of Alzheimer's disease

The ubiquitin proteasomal system: a potential target for the management of Alzheimer's disease

Anti-inflammatory effects of neurotrophic therapy (a pilot study)

Progression of Cognitive Deficit in Older People with Mild Cognitive Impairment Treated with Cerebrolysin

Contact Info

Product

Resources

About